July 27, 2015
Weil’s Antitrust team is representing Allergan plc, a leading global pharmaceutical company, in the recently announced sale of its global generic pharmaceuticals business to Teva Pharmaceutical Industries Ltd., a transaction valued at approximately $40.5 billion. “This transaction will accelerate Allergan's evolution into a branded Growth Pharma leader,” said Brent Saunders, CEO and President of Allergan, in a press release.
Weil previously served as antitrust counsel to Allergan in its approximately $2.1 billion acquisition of KYTHERA Biopharmaceuticals Inc. In addition, Weil served as antitrust counsel to Actavis plc in its approximately $70.5 billion acquisition of Allergan, the combined company assumed the Allergan name.
For more information on the transaction, view Allergan’s press release.